China-based Jiuzhitang Co. Ltd (SHE: 000989) announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 biologic product, human bone marrow mesenchymal stem cells (hBMSCs), to treat autism spectrum disorder (ASD). This marks a significant step forward in exploring novel therapeutic options for ASD.
Product Details
The hBMSCs product is a cryopreserved stem cell preparation derived from the bone marrow of healthy young adult donors. It is cultured under simulated low oxygen conditions throughout the process to maintain its viability and therapeutic potential.
Understanding Autism Spectrum Disorder
Autism spectrum disorder (ASD) is a neurological and developmental disorder that affects social, communication, and behavioral skills. It typically manifests in early childhood and is characterized by difficulties in social communication, repetitive behaviors, and narrow interests. The symptoms and severity vary widely among individuals, and currently, there is no specific treatment method.
Clinical Trial Significance
The approval of the clinical trial for hBMSCs represents a promising avenue for ASD treatment research. By leveraging the potential of stem cell therapy, Jiuzhitang aims to address the unmet medical needs of ASD patients and potentially improve their quality of life.-Fineline Info & Tech
Leave a Reply